Horizon Oncology Research, Inc.

Lafayette, Indiana 47908

0 studies enrolling now · 29 studies all time

What they study most

Advanced Solid Tumors, Breast Cancer, Cancer and Chemotherapy Related Anemia, Carcinoma, Non-Small-Cell Lung, Chemotherapy-induced Peripheral Neuropathy, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia, Colorectal Cancer, Extensive-Stage Small-Cell Lung Cancer, HER-2 Gene Amplification, HER2-Negative Metastatic Breast Cancer

Studies at this site

• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study — Running, not enrolling
• Connect® Myeloid Disease Registry — Stopped early
• A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma — Completed
• Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients — Stopped early
• A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) — Completed
• Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) — Completed
• Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC — Completed
• PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) — Completed
• Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma — Completed
• A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma — Completed
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma — Completed
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
• Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting — Completed
• A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors — Stopped early
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) — Completed
• Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors — Completed
• Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer® — Completed
• A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols — Stopped early
• Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer — Completed
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients — Completed
• A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) — Completed
• Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment — Completed
• Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer — Completed
• A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) — Completed
• An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia — Completed
• Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Completed
• A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer — Completed
• A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy — Completed
• A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors — Completed